Literature DB >> 15847795

Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.

Diana Wouters1, Hans D Wiessenberg, Margreet Hart, Peter Bruins, Alexandre Voskuyl, Mohamed R Daha, C Erik Hack.   

Abstract

Classical pathway activation is often assessed by measuring circulating levels of activated C4. However, this parameter does not discriminate between activation through the classical or the lectin pathway. We hypothesized that during classical pathway activation, complexes are formed between C1q and activated C4 or C3. Using ELISA, we investigated whether such complexes constitute specific markers for classical pathway activation. In vitro, C1q-C3d/C4d complexes were generated upon incubation of normal recalcified plasma with aggregated IgG or an anti-C1q mAb that activates C1 (mAb anti-C1q-130). In contrast, during incubation with C1s or trypsin, C1q-C3d/C4d complexes were not generated, which excludes an innocent bystander effect. Additionally, C1q-C3d/C4d complexes were not generated during activation of the alternative or the lectin pathway. Repeated freezing and thawing did not influence levels of C1q-C3d/C4d complexes in recalcified plasma. To measure C1q-complement complexes in plasma samples, we separated unbound complement proteins from C1q-C3d/C4d complexes in the samples prior to testing with ELISA. In samples from patients undergoing cardiopulmonary bypass surgery or suffering from rheumatoid arthritis, we found higher levels of C1q-C4 complexes than in samples from healthy individuals. We conclude that complexes between C1q and C4 or C3 are specific markers of classical complement pathway activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15847795     DOI: 10.1016/j.jim.2004.12.018

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

Authors:  T C T M van der Pouw Kraan; C A Wijbrandts; L G M van Baarsen; A E Voskuyl; F Rustenburg; J M Baggen; S M Ibrahim; M Fero; B A C Dijkmans; P P Tak; C L Verweij
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

2.  Mild hypothermia inhibits systemic and cerebral complement activation in a swine model of cardiac arrest.

Authors:  Ping Gong; Hong Zhao; Rong Hua; Mingyue Zhang; Ziren Tang; Xue Mei; Juan Cui; Chunsheng Li
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-11       Impact factor: 6.200

3.  Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2.

Authors:  Barbro Selander; Ulla Mårtensson; Andrej Weintraub; Eva Holmström; Misao Matsushita; Steffen Thiel; Jens C Jensenius; Lennart Truedsson; Anders G Sjöholm
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

4.  Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.

Authors:  Osama A Hamad; Per H Nilsson; Diana Wouters; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

5.  SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb.

Authors:  Catherine A Foss; Liudmila Kulik; Alvaro A Ordonez; Sanjay K Jain; V Michael Holers; Joshua M Thurman; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

6.  Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation.

Authors:  Nuzhat Maisha; Tobias Coombs; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2020-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.